Toward a Harm Reduction Approach to Cannabis Use Disorder
American Journal of Psychiatry · 01.02.2024 · 181 (2) · 98-99
DOI: 10.1176/appi.ajp.20230381 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Psychiatry, erschienen am 01.02.2024. Verfasst von Lewei Allison Lin und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, University of Michigan, Ann Arbor, Mich. (Lin, Bonar, Coughlin); VA Center for Clinical Management Research (CCMR), VA Ann …. Hauptthemen laut MEDLINE: Substance-Related Disorders, Marijuana Abuse, Cannabis. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 8 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: HSRD VA, NIAAA NIH HHS.
Abstract (Originalsprache)
cannabis; harm reduction; substance use disorder; addictionCannabis is now legal for recreational and/or medical use in most U.S. states.Decriminalizing cannabis use and possession is important for eliminating decades-old racist policies, but is occurring alongside increasing consumption, particularly of more potent products (e.g., vape liquids, concentrates).In the U.S., 52.5 million people aged 12+ used cannabis in the past year and every 12 seconds, someone uses cannabis for the first time (1).Most people who use cannabis do not develop problems and, indeed, there can be both subjective and medical benefits of use (2), though perceived medical benefits are often unsubstantiated by evidence.However, there is a growing sub-group experiencing harms.Approximately 22% of those who use cannabis develop a cannabis use disorder, characterized by persistent use despite clinically significant impairment (e.g., failure to fulfill roles) and/or distress (3).Potential negative consequences of excessive cannabis use include physical (e.g., cannabis hyperemesis, respiratory problems), mental (e.g., worsening anxiety, psychosis, cognitive impairments) and social impacts (e.g., academic and family problems), yet treatment rates (~5%) for cannabis use disorder are exceedingly low (4).Cannabis has high public support; most Americans favor some form of legalization and many view cannabis as a benign substance.This social acceptability is accompanied by beliefs that cannabis provides many unproven benefits.Indications for obtaining medical cannabis include conditions with evidential support (e.g., chemotherapy-induced nausea/ vomiting) and conditions with minimal or no evidence (e.g., Parkinson Disease, mental health conditions (2)).This climate makes it challenging for individuals and clinicians to recognize and discuss cannabis-related harms and treatment needs.For example, irritability, anxiety, and sleep problems may not be readily identified as symptoms of cannabis withdrawal, leading patients to resume cannabis to reduce these symptoms.Further,
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Psychiatry, University of Michigan, Ann Arbor, Mich. (Lin, Bonar, Coughlin); VA Center for Clinical Management Research (CCMR), VA Ann Arbor Healthcare System, Ann Arbor, Mich. (Lin).
Förderung
- HSRD VA
- NIAAA NIH HHS
Zitieren
APA
Lin, L. A., Bonar, E. E., & Coughlin, L. N. (2024). Toward a Harm Reduction Approach to Cannabis Use Disorder. American Journal of Psychiatry, 181(2), 98-99. https://doi.org/10.1176/appi.ajp.20230381
Vancouver
Lin LA, Bonar EE, Coughlin LN. Toward a Harm Reduction Approach to Cannabis Use Disorder. American Journal of Psychiatry. 2024;181(2):98-99. doi:10.1176/appi.ajp.20230381
BibTeX
@article{Lin2024,
author = {Lin, Lewei Allison and Bonar, Erin E and Coughlin, Lara N},
title = {Toward a Harm Reduction Approach to Cannabis Use Disorder},
journal = {American Journal of Psychiatry},
year = {2024},
volume = {181},
number = {2},
pages = {98--99},
doi = {10.1176/appi.ajp.20230381}
}
EUVIMED